Ropeginterferon alfa-2b (BESREMi®)

DRUG3 trials

Sponsors

AOP Orphan Pharmaceuticals AG, The University of Hong Kong, Federico II University

Conditions

Essential ThrombocythaemiaPolycytemia VeraPost Essential Thrombocythaemia Myelofibrosis (PET-MF)Post Polycythemia Myelofibrosis (PPV MF)Primary Myelofibrosis (PMF)

Phase 2

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

RecruitingNCT06770842

The University of Hong KongPost Essential Thrombocythaemia Myelofibrosis (PET-MF), Post Polycythemia Myelofibrosis (PPV MF), Primary Myelofibrosis (PMF)

Start: 2025-03-01End: 2027-12-31Target: 20Updated: 2025-06-11

Phase 3

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Active, not recruitingNCT06514807

AOP Orphan Pharmaceuticals AGEssential Thrombocythaemia

Start: 2023-12-04End: 2028-03-15Target: 117Updated: 2024-12-19

Unknown Phase

Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study

Not yet recruitingNCT07282132

Federico II UniversityPolycytemia Vera

Start: 2026-01-10End: 2026-03-31Target: 150Updated: 2025-12-15

Related Papers

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Blood2025-11-03

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood2024-11-05